The Motley Fool

Twiggy Forrest backed Invex Therapeutics has now doubled since its IPO

Invex Therapeutics Ltd (ASX: IXC) shares have now doubled from their July 3 initial public offer price of 40 cents to 85 cents this afternoon as investors turn bullish on a company backed by Fortescue Metals Group Limited (ASX: FMG) chairman Andrew Forrest.

According to its prospectus, “Invex is a biopharmaceutical company focused on the development of efficacious treatments for neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury.” 

The company has taken the intellectual property of Dr Alexandra J Sinclair from the UK’s University of Birmingham, with Dr Sinclair being appointed the chief scientific officer of Invex as it now attempts to commercialise its potential treatments for intracranial or ‘within the skull’ pressures. 

The company has no revenue, so it’s basically another speculative ASX-listed biotech business now worth $42.5 million based on 50 million shares on issue, with $12 million raised to go towards funding its “later stage research and development program”.

A cynic might suggest you’d need as much cash to burn as Andrew Forrest to justify investing in this kind of business, with Mr Forrest also an early backer of ASX biotech and capital sinkhole Admedus Ltd (ASX: AHZ).

That’s not to say Invex can’t go onto be a big success, it’s just hat it has a very long road ahead of it and unless you’re a medical expert on intracranial pressure treatments it’s difficult to know its chances. 

One ASX Stock For An Estimated $US22 Billion Marijuana Market

A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming. To the tune of an estimated $US22 billion.

Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.

Here's the best part: we think there's one ASX stock that's uniquely positioned to profit immensely from this explosive new industry... taking savvy investors along for what could be one heck of a ride.

AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.

Simply click below to learn more on how you can profit from the coming cannabis boom.

Click here to find out more


Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

NEW. Five Cheap and Good Stocks to Buy in 2019…

Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield…

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.